{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"BioBreakthroughs","title":"#14 – Simon Arkell, CEO and Co-Founder of Synthetica Bio","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/beb9b68f\"></iframe>","width":"100%","height":180,"duration":910,"description":"Join us on the latest episode! Our Guest: Simon Arkell, CEO and Co-Founder of Synthetica BioWhat you'll get out of this episode:- Simon Arkell, CEO of Synthetica Bio, sheds light on biopharma's future- Originally an Australian athlete, Arkell became a U.S.-based entrepreneur, focusing on machine learning, data analytics, and patient care.- His standout contribution was through DeepLens in precision oncology.- Synthetica Bio aims to provide advanced data solutions in biopharma using generative AI, addressing the industry's data analysis challenges.- Despite abundant data, biopharma grapples with analysis bottlenecks due to task-specific traditional models.- Synthetica Bio differentiates itself with versatile data interpretation using generative AI and a unique cloud-based microservices architecture.- With backing from major venture capitalists and strategic partnerships, Synthetica Bio is on track for significant industry innovation.- Overall, Synthetica Bio is driving transformation in biopharma, maximizing generative AI's potential.To learn more about Synthetica Bio: https://syntheticabio.ai/Our sponsors for this episode are:Sage Growth Partners https://sage-growth.com/FlipMD by GoodRX https://www.goodrx.com/Quantum Health https://quantum-health.com/","thumbnail_url":"https://img.transistorcdn.com/roxGfgcNItysBs3fg55SsdSx4l_Pbz86Ktm2KMDYkR4/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzQwNjg1LzE2ODE5/MzQxODQtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}